Patents Assigned to RAZE THERAPEUTICS, INC.
  • 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
    Patent number: 11634412
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: April 25, 2023
    Assignee: Raze Therapeutics, Inc.
    Inventor: Nello Mainolfi
  • 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
    Patent number: 11535593
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: December 27, 2022
    Assignee: Raze Therapeutics, Inc.
    Inventor: Nello Mainolfi
  • Caffeine inhibitors of MTHFD2 and uses thereof
    Patent number: 11370792
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: June 28, 2022
    Assignee: Raze Therapeutics, Inc.
    Inventors: Nello Mainolfi, Mikel P. Moyer, Eddine Saiah, Cristina Lecci, Robert David Matthew Pace, Heather Tye, Julia Vile
  • SHMT inhibitors and uses thereof
    Patent number: 11091451
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: August 17, 2021
    Assignee: RAZE THERAPEUTICS, INC.
    Inventor: Nello Mainolfi
  • 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
    Patent number: 11014882
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: May 25, 2021
    Assignee: RAZE THERAPEUTICS, INC.
    Inventor: Nello Mainolfi
  • 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
    Patent number: 10954220
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: March 23, 2021
    Assignee: RAZE THERAPEUTICS, INC.
    Inventor: Nello Mainolfi